Navigation Links
Will individuals with Alzheimer's disease benefit from cataract surgery?
Date:6/25/2009

CLEVELANDA multi-institutional team of researchers, led by the Mandel School of Applied Social Sciences at Case Western Reserve University, will begin a five-year, $2.9 million National Institutes of Health-funded study. They will examine the lives of patients with both cataracts and Alzheimer's disease (AD) to document how restored vision improves everyday life for people with dementia.

"This project addresses a major social justice issue in the disparity in vision care of persons diagnosed with Alzheimer's disease," said Grover "Cleve" Gilmore, dean of the Case Western Reserve Mandel School and principal investigator of the study.

Gilmore will lead faculty from the departments of Ophthalmology and Visual Sciences and Neurology at the Case Western Reserve University School of Medicine and physicians from the Eye Institute and Neurological Institute at University Hospitals and the Division of Ophthalmology at MetroHealth Medical Center.

In 20 years of research, Gilmore has found people with dementia lose their ability to see objects in medium- and low-contrast environments, but boosting the contrast of objects improves their ability to move around their homes; eat better; read; and do other simple, everyday tasks.

Cataracts cloud and blur the vision in the eye causing AD patients additional problems. If untreated, the cataracts lead to blindness, but sight can be restored with surgery to remove the cataract.

Co-investigator Jonathan Lass, M.D., the Charles I Thomas Professor and chair of the department of ophthalmology and visual sciences at the Case Western Reserve School of Medicine and director of the Eye Institute at University Hospitals, says, surprisingly, a preliminary study has shown 10 percent of patients over 65 who have an eye exam have some memory impairment along with cataracts. Most people start to show signs of cataracts in their early 60s.

"This research is important because we are a v
'/>"/>

Contact: Susan Griffith
susan.griffith@case.edu
216-368-1004
Case Western Reserve University
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Study finds cancer is the second most frequent cause of death in individuals with schizophrenia
2. JustAnswer(R) and Glaucoma Research Foundation Help Individuals See the Light in Preventing Blindness
3. Individuals Who Apply Pesticides Are Found to Have Double the Risk of Blood Disorder
4. RA individuals from lower GDP countries keep working despite worse symptoms than richer countries
5. Companion Global Healthcare Inc. Offers Additional Hospital Choices to Employers, Individuals Looking to Save on Fully Credentialed Health Care
6. Ironman Competitor with Diabetes Inspires Individuals with Diabetes to Live Without Limits
7. Explorers Bounty Coffees and Chocolates Helping Individuals Reverse the Aging Process
8. QualityMetric Offers Way to Measure the Impact of Sleep Problems on Individuals and Groups
9. Eleventh Annual Welcome Back Awards Program Honors Individuals who Positively Impact the Depression Community
10. arc Thrift Stores to Honor Individuals and Businesses Who Support People With Developmental Disabilities
11. NSVRC Honors 12 Individuals With Award for Sexual Assault Awareness Month
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine Technology:Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 2Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 3Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 4Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 5Byetta Treatment for Three and a Half Years Associated with,Reductions in Cardiovascular Risk Factors in People with Type 2,Diabetes 6Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6